BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Coalition led by Iraqi PM al-Sudani wins parliamentary elections - 2Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- 3Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- 4Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- 5Violence 'never part' of break-in plan, court told
- 6 Savvy Locks for Lofts
- Figure out How to Establish a long term connection with Your Handshake
- Pick Your Top Method for starting the Morning
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- The Best Portable Applications for Emotional wellness and Prosperity
- Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- How comfort foods trigger pleasure in our brains
